| Date Filed | Type | Description |
| 10/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/25/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/28/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/28/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Offer Letter, between the Company and R. Brent Jones",
"RADNOR, Pa. - July 13, 2023 - Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced that R. Brent Jones will join the company as Executive Vice President and Chief Financial Officer, effective August 7, 2023. Over a nearly 30-year career, Mr. Jones has served as chief financial officer for several public and private life sciences companies and, previously, as a senior investment banker. He is currently Executive Vice President, Chief Financial Officer and Chief Operating Officer at LifeScan Global Corporation, a global leader in blood glucose monitoring and digital health technology, where he is responsible for all aspects of LifeScan's global finance and..." |
|
| 07/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 05/30/2023 |
SD
| Form SD - Specialized disclosure report: |
| 05/15/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"RADNOR, Pa. - May 15, 2023 - Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced that Executive Vice President and Chief Financial Officer Thomas A. Szlosek will be leaving the Company effective August 2, 2023 to pursue an opportunity outside the life sciences industry. Mr. Szlosek will continue in his role through the announcement of the Company's second quarter earnings. Avantor has initiated a search to identify the Company's next CFO. “On behalf of the entire Avantor team, I thank Tom for all of his contributions. He has been a great partner as we took Avantor public in 2019, expanded the global enterprise, and built a resilient foundation to drive ..." |
|
| 05/11/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 04/28/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/31/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/31/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 5.8% stake in AVANTOR INC |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 9.2% stake in Avantor Inc. |
| 02/03/2023 |
8-K
| Quarterly results |
| 02/01/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/18/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/28/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/28/2022 |
8-K
| Quarterly results |
| 09/13/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/10/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/29/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/28/2022 |
8-K
| Quarterly results |
| 05/31/2022 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 05/31/2022 |
SD
| Form SD - Specialized disclosure report: |
| 05/17/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 05/13/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/28/2022 |
8-K
| Quarterly results |
|